- Home
- CEV vs CUE Comparison
CEV vs CUE Comparison
Compare CEV & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEV
- CUE
- Stock Information
- Founded
- CEV 1999
- CUE 2014
- Country
- CEV United States
- CUE United States
- Employees
- CEV N/A
- CUE N/A
- Industry
- CEV Finance/Investors Services
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- CEV Finance
- CUE Health Care
- Exchange
- CEV Nasdaq
- CUE Nasdaq
- Market Cap
- CEV 67.8M
- CUE 58.9M
- IPO Year
- CEV N/A
- CUE 2018
- Fundamental
- Price
- CEV $9.81
- CUE $0.78
- Analyst Decision
- CEV
- CUE Strong Buy
- Analyst Count
- CEV 0
- CUE 3
- Target Price
- CEV N/A
- CUE $3.00
- AVG Volume (30 Days)
- CEV 19.6K
- CUE 161.8K
- Earning Date
- CEV 01-01-0001
- CUE 05-20-2025
- Dividend Yield
- CEV 4.23%
- CUE N/A
- EPS Growth
- CEV N/A
- CUE N/A
- EPS
- CEV 0.36
- CUE N/A
- Revenue
- CEV N/A
- CUE $9,287,000.00
- Revenue This Year
- CEV N/A
- CUE N/A
- Revenue Next Year
- CEV N/A
- CUE $25.99
- P/E Ratio
- CEV $29.36
- CUE N/A
- Revenue Growth
- CEV N/A
- CUE 69.16
- 52 Week Low
- CEV $8.83
- CUE $0.45
- 52 Week High
- CEV $10.91
- CUE $2.26
- Technical
- Relative Strength Index (RSI)
- CEV 51.91
- CUE 46.03
- Support Level
- CEV $9.74
- CUE $0.71
- Resistance Level
- CEV $9.86
- CUE $0.78
- Average True Range (ATR)
- CEV 0.08
- CUE 0.06
- MACD
- CEV 0.03
- CUE 0.01
- Stochastic Oscillator
- CEV 81.58
- CUE 46.11
About CEV Eaton Vance California Municipal Income Trust Shares of Beneficial Interest
Eaton Vance CA Muni Income Trust is a non-diversified closed-end investment company. The company's investment objective is to provide current income exempt from regular federal income tax and California state personal income taxes. It invests in municipal obligations, issued by the State of California or its political subdivisions, agencies, authorities and instrumentalities and also has some exposure to corporate bonds.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.